SCHEMBL5137499

SCHEMBL5137499

CCc1ccc(CN(CCC(C)C)Cc2cnc(-c3ccccc3)n2CCc2ccccc2)cc1

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.36
OPRM1 P35372 2/20 0.35
OPRD1 P41143 2/20 0.35
OPRK1 P41145 2/20 0.35
BCHE P06276 3/20 0.34
CASR P41180 1/20 0.33
MEN1 O00255 1/20 0.33
LMNA P02545 1/20 0.33
KMT2A Q03164 1/20 0.33
KDM4E B2RXH2 1/20 0.32
HSD17B10 Q99714 1/20 0.32
RECQL P46063 1/20 0.32
CCR3 P51677 1/20 0.32
ALDH1A1 P00352 1/20 0.32
TSHR P16473 1/20 0.32
MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5245866 0.88 OPRM1 (0.38) HSD11B1OPRM1OPRD1OPRK1BCHE
SCHEMBL5136558 0.86 BCHE (0.35) HSD11B1OPRM1OPRD1OPRK1BCHE
SCHEMBL5153427 0.84 MEN1 (0.37) OPRM1OPRD1OPRK1BCHECASR
SCHEMBL5135667 0.84 HSD11B1 (0.44) HSD11B1OPRM1OPRD1OPRK1BCHE
SCHEMBL5152777 0.83 OPRM1 (0.36) OPRM1OPRD1OPRK1BCHECASR
SCHEMBL5075147 0.82 TSHR (0.39) HSD11B1MEN1KMT2AKDM4EHSD17B10
SCHEMBL5070162 0.80 TSHR (0.47) HSD11B1LMNAKDM4EHSD17B10ALDH1A1
SCHEMBL5075074 0.79 TSHR (0.46) HSD11B1OPRM1OPRD1OPRK1BCHE
SCHEMBL5072355 0.78 HSD11B1 (0.45) HSD11B1OPRM1OPRD1OPRK1BCHE
SCHEMBL5134920 0.78 HSD11B1 (0.44) HSD11B1OPRM1OPRD1OPRK1BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed